Puma Biotechnology, Inc. provided earnings guidance for the second quarter of 2024. For the quarter, the company expects Net loss to be $6 million - $9 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.02 USD | +0.50% | -3.60% | -7.16% |
May. 17 | Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial | RE |
May. 02 | Transcript : Puma Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.16% | 194M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+36.36% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+27.49% | 12.08B | |
+22.40% | 11.94B |
- Stock Market
- Equities
- PBYI Stock
- News Puma Biotechnology, Inc.
- Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter of Full Year of 2024